Several analysts have recently updated their ratings and price targets for Medtronic (NYSE: MDT):

  • 11/23/2017 – Medtronic had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $99.00 price target on the stock.
  • 11/23/2017 – Medtronic was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Medtronic exited the fiscal second quarter on a mixed note. While the company demonstrated improved segmental performances at CER, escalating costs and expenses continue to weigh on the bottom line. Unfavorable currency translation also acted as a dampener. On the bright side, all major business groups contributed to solid top-line growth at CER, which highlighted sustainability across groups and regions, in addition to displaying successful integration and achievement of synergy targets. We are also encouraged by the solid growth trend in the United States as well as healthy global acceptance of its advanced therapies. The recent receipt of FDA approval and commercial launch of Azure pacemakers with BlueSync technology buoy optimism. Apart from product innovation, the company is focusing on geographical diversification of its businesses. The stabilizing trend in the global Cardiac Rhythm & Heart Failure (CRHF) market is another upside.”
  • 11/22/2017 – Medtronic had its “hold” rating reaffirmed by analysts at Northland Securities. They now have a $80.00 price target on the stock.
  • 11/22/2017 – Medtronic had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $94.00 price target on the stock.
  • 11/22/2017 – Medtronic had its price target raised by analysts at Stifel Nicolaus from $83.00 to $85.00. They now have a “hold” rating on the stock.
  • 11/19/2017 – Medtronic was given a new $92.00 price target on by analysts at SunTrust Banks, Inc.. They now have a “buy” rating on the stock.
  • 11/9/2017 – Medtronic had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $94.00 price target on the stock. They wrote, “On 11/8/17, MDT preannounced F2Q18 revenue of $7.050B (up 3% organic Y/Y) vs. consensus of $6.897M. The impact from Hurricane Maria was revised down to ~$60M from ~$250M, which equates to ~1% in quarterly revenue growth and ~$0.03 in non-GAAP EPS. MDT did not update its FY18 revenue or EPS guidance in the press release but did reaffirm F2Q18 non-GAAP EPS growth of flat to slightly up, excluding the ~$0.03 headwind. MDT is scheduled to report full F2Q18 results on 11/21/17 and we intend to wait until then to update our model.””
  • 11/3/2017 – Medtronic had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $96.00 price target on the stock.
  • 11/3/2017 – Medtronic had its “buy” rating reaffirmed by analysts at Cowen Inc. They now have a $95.00 price target on the stock.
  • 10/10/2017 – Medtronic had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $89.00 price target on the stock, down previously from $92.00.
  • 10/10/2017 – Medtronic had its price target lowered by analysts at Needham & Company LLC from $95.00 to $94.00. They now have a “buy” rating on the stock.
  • 10/9/2017 – Medtronic had its “market perform” rating reaffirmed by analysts at Leerink Swann. They now have a $85.00 price target on the stock, down previously from $88.00.
  • 10/9/2017 – Medtronic had its price target lowered by analysts at Stifel Nicolaus from $91.00 to $83.00. They now have a “hold” rating on the stock.
  • 10/9/2017 – Medtronic had its price target lowered by analysts at Royal Bank Of Canada from $90.00 to $85.00. They now have an “outperform” rating on the stock.
  • 10/9/2017 – Medtronic was downgraded by analysts at Wells Fargo & Company from an “outperform” rating to a “market perform” rating. They now have a $83.00 price target on the stock, down previously from $93.00.

Shares of Medtronic PLC (NYSE:MDT) traded up $0.91 on Tuesday, hitting $80.78. 3,372,765 shares of the stock were exchanged, compared to its average volume of 4,957,406. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.05 and a current ratio of 2.40. Medtronic PLC has a fifty-two week low of $69.35 and a fifty-two week high of $89.72. The stock has a market cap of $108,100.00, a PE ratio of 17.51, a price-to-earnings-growth ratio of 2.24 and a beta of 1.00.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.08. Medtronic had a net margin of 16.93% and a return on equity of 12.63%. The business had revenue of $7.05 billion during the quarter, compared to analysts’ expectations of $7.05 billion. During the same period last year, the company posted $1.12 EPS. The company’s revenue was down 4.0% on a year-over-year basis. equities analysts expect that Medtronic PLC will post 4.77 earnings per share for the current year.

In other Medtronic news, EVP Bryan C. Hanson sold 16,000 shares of Medtronic stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $79.02, for a total value of $1,264,320.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Omar Ishrak sold 140,407 shares of Medtronic stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $81.63, for a total transaction of $11,461,423.41. Following the completion of the sale, the chief executive officer now directly owns 668,503 shares of the company’s stock, valued at $54,569,899.89. The disclosure for this sale can be found here. Over the last three months, insiders have sold 172,407 shares of company stock valued at $13,974,223. Corporate insiders own 0.31% of the company’s stock.

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with MarketBeat.com's FREE daily email newsletter.